Oxaliplatin

Oxaliplatin
Clinical data
Trade names	Eloxatin
AHFS/Drugs.com	Monograph
MedlinePlus	a607035
License data	US DailyMed: Oxaliplatin;
Routes of; administration	Intravenous
ATC code	L01XA03 (WHO) ;
Legal status
Legal status	US: WARNINGRx-only;
Pharmacokinetic data
Bioavailability	Complete
Elimination half-life	~10 – 25 minutes
Excretion	Kidney
Identifiers
	IUPAC name [(1R,2R)-cyclohexane-1,2-diamine](ethanedioato-O,O')platinum(II);
CAS Number	61825-94-3 ;
PubChem CID	77994;
DrugBank	DB00526 ;
ChemSpider	8062727 ;
UNII	04ZR38536J;
KEGG	D01790 ;
ChEMBL	ChEMBL414804 ;
PDB ligand	1PT (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID0036760 ;
ECHA InfoCard	100.150.118
Chemical and physical data
Formula	C8H14N2O4Pt
Molar mass	397.294 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O1C(=O)C(=O)O[Pt-2]12[NH2+]C0CCCCC0[NH2+]2;
	(what is this?) (verify)

Oxaliplatin, sold under the brand name Eloxatin among others, is a cancer medication (platinum-based antineoplastic class) used to treat colorectal cancer. It is given by injection into a vein.

Common side effects include numbness, feeling tired, nausea, diarrhea, and low blood cell counts. Other serious side effects include allergic reactions. Use in pregnancy is known to harm the baby. Oxaliplatin is in the platinum-based antineoplastic family of medications. It is believed to work by blocking the duplication of DNA.

Oxaliplatin was patented in 1976 in Japan and approved for medical use in 1996 in Europe. It is on the 2023 World Health Organization's List of Essential Medicines.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.